ES2384278T3 - IL-1-alfa para su uso en un procedimiento de tratamiento de placas ateroscleróticas - Google Patents

IL-1-alfa para su uso en un procedimiento de tratamiento de placas ateroscleróticas Download PDF

Info

Publication number
ES2384278T3
ES2384278T3 ES07734572T ES07734572T ES2384278T3 ES 2384278 T3 ES2384278 T3 ES 2384278T3 ES 07734572 T ES07734572 T ES 07734572T ES 07734572 T ES07734572 T ES 07734572T ES 2384278 T3 ES2384278 T3 ES 2384278T3
Authority
ES
Spain
Prior art keywords
mice
apoe
dpp
serum
atherosclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07734572T
Other languages
English (en)
Spanish (es)
Inventor
John Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XBIOTECH Inc
Xbiotech Inc
Original Assignee
XBIOTECH Inc
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XBIOTECH Inc, Xbiotech Inc filed Critical XBIOTECH Inc
Application granted granted Critical
Publication of ES2384278T3 publication Critical patent/ES2384278T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Oxide Ceramics (AREA)
ES07734572T 2006-05-15 2007-05-15 IL-1-alfa para su uso en un procedimiento de tratamiento de placas ateroscleróticas Active ES2384278T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80002906P 2006-05-15 2006-05-15
US800029P 2006-05-15
PCT/IB2007/001264 WO2007132338A2 (en) 2006-05-15 2007-05-15 IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS

Publications (1)

Publication Number Publication Date
ES2384278T3 true ES2384278T3 (es) 2012-07-03

Family

ID=38694276

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07734572T Active ES2384278T3 (es) 2006-05-15 2007-05-15 IL-1-alfa para su uso en un procedimiento de tratamiento de placas ateroscleróticas

Country Status (9)

Country Link
US (1) US20090191149A1 (https=)
EP (1) EP2021033B1 (https=)
JP (1) JP2009537507A (https=)
CN (1) CN101448528A (https=)
AT (1) ATE551365T1 (https=)
AU (1) AU2007251239B2 (https=)
CA (1) CA2652274A1 (https=)
ES (1) ES2384278T3 (https=)
WO (1) WO2007132338A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1915620T3 (da) 2005-08-02 2010-10-04 Xbiotech Inc Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN102580086A (zh) * 2006-05-22 2012-07-18 埃克斯生物科技公司 使用抗IL-1α抗体治疗癌症
CA2726345C (en) 2008-05-30 2018-08-28 John Simard Interleukin-1 alpha antibodies and methods of use
AU2009291536B2 (en) * 2008-09-12 2012-08-16 Xbiotech Inc. Targeting pathogenic monocytes
EP2569640A1 (en) 2010-05-12 2013-03-20 The University of Birmingham Biomarker
KR102167261B1 (ko) 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
US10294296B2 (en) 2010-08-23 2019-05-21 Xbiotech, Inc. Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
JP6456015B2 (ja) * 2013-07-19 2019-01-23 国立大学法人三重大学 閉塞性動脈硬化症モデル動物、るい痩研究用モデル動物、及び全身性アミロイドーシスモデル動物としての非ヒト哺乳動物
CN105175504A (zh) * 2015-09-08 2015-12-23 苏州普罗达生物科技有限公司 血管性血友病因子抑制多肽及其应用
CN105175503A (zh) * 2015-09-08 2015-12-23 苏州普罗达生物科技有限公司 因子viii抑制多肽及其应用
CA3053231A1 (en) 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802402D0 (sv) * 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
WO2000009118A1 (en) * 1998-08-13 2000-02-24 The Wistar Institute Methods for reducing atherosclerotic plaques
US20030040617A9 (en) * 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030232054A1 (en) * 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
DK1915620T3 (da) 2005-08-02 2010-10-04 Xbiotech Inc Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
CN101267834B (zh) 2005-09-28 2013-06-05 赛托斯生物技术公司 白介素-1偶联物及其用途
CA2726345C (en) * 2008-05-30 2018-08-28 John Simard Interleukin-1 alpha antibodies and methods of use
AU2009291536B2 (en) * 2008-09-12 2012-08-16 Xbiotech Inc. Targeting pathogenic monocytes

Also Published As

Publication number Publication date
ATE551365T1 (de) 2012-04-15
WO2007132338A3 (en) 2008-06-12
CA2652274A1 (en) 2007-11-22
CN101448528A (zh) 2009-06-03
EP2021033A4 (en) 2010-02-24
EP2021033B1 (en) 2012-03-28
EP2021033A2 (en) 2009-02-11
JP2009537507A (ja) 2009-10-29
AU2007251239A1 (en) 2007-11-22
US20090191149A1 (en) 2009-07-30
WO2007132338A2 (en) 2007-11-22
AU2007251239B2 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
ES2384278T3 (es) IL-1-alfa para su uso en un procedimiento de tratamiento de placas ateroscleróticas
US20110008282A1 (en) IL-1alpha immunization induces autoantibodies protective against atherosclerosis
Sonderegger et al. Neutralization of IL‐17 by active vaccination inhibits IL‐23‐dependent autoimmune myocarditis
US11110155B2 (en) Immunotherapeutic compositions for the treatment of Alzheimer's disease
Bates et al. Mucosal adjuvant activity of flagellin in aged mice
O'Hara et al. Generation of protective pneumococcal-specific nasal resident memory CD4+ T cells via parenteral immunization
Ortega-Pierres et al. Induction of protection in murine experimental models against Trichinella spiralis: an up-to-date review
JP6955324B2 (ja) 医薬化合物を評価するための新規動物モデル
US8632781B2 (en) Immunogenic compounds comprising peptides of IL1β
EA014531B1 (ru) Антиамилоидные иммуногенные композиции, способы и применения
Yang et al. Immunization with a live-attenuated RH: Δ NPT1 strain of Toxoplasma gondii Induces strong protective immunity against toxoplasmosis in mice
JP4188353B2 (ja) 強化ワクチン
Constantinescu et al. Modulation of susceptibility and resistance to an autoimmune model of multiple sclerosis in prototypically susceptible and resistant strains by neutralization of interleukin-12 and interleukin-4, respectively
JP5202330B2 (ja) 細菌のラフ型株の製造方法およびその用途
Ashany et al. Analysis of autoantibody production in SCID-systemic lupus erythematosus (SLE) chimeras
Schellekens Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasia
JP2006507260A (ja) インターロイキン−１５（ｉｌ−１５）を含むワクチン組成物
JP2024534901A (ja) シヌクレイノパチーの予防及び治療のための方法
Gopen et al. Mechanisms underlying autoimmune inner ear disease
EA009937B1 (ru) Индукторы монопараиммунитета, основанные на ослабленных вирусах миксомы кролика
Shibahara Development of Immunocontraceptives in Female
Kaur et al. Textbook of Immunology
CN120648712A (zh) 新型mRNA疫苗的制备及其在神经退行性疾病治疗中的应用
Ribatti Immunology in the Twentieth Century: From Basic Science to Clinical Application
Nandi Immunology: At a Glance